RxDoctor Payments Data

Dusan Stanojevic, MD

Cardiovascular Disease · Olathe, KSNPI 1770782229

Payments from drug & device makers

$3,564in general payments, 2019–2025

Across 78 payments — averaging $45.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Boston Scientific$527
  • Abbott$369
  • Cardiva Medical, Inc.$126
  • Edwards Lifesciences$43
  • Amgen$43
  • plus $224 from 10 others

What the payments were for

  • Travel & lodging$1,56344%
  • Food & beverage$2,00156%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,564 in reported general payments places this provider in the 55th percentile of 175 cardiovascular disease providers in Kansas.

See all cardiovascular disease providers in Kansas

Medicare billing

Part B allowed, 2024
$223,757
Medicare patients
1,054
Services billed
2,818

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban346$336,014
EntrestoSacubitril/Valsartan98$100,943
XareltoRivaroxaban86$75,070
JardianceEmpagliflozin33$31,619
FarxigaDapagliflozin Propanediol33$29,743
Praluent PenAlirocumab15$13,459
Repatha SureclickEvolocumab17$12,640
Ranolazine ErRanolazine42$5,216
Atorvastatin Calcium530$4,246
Metoprolol Succinate374$3,791
Potassium Chloride185$3,621
Isosorbide Mononitrate ErIsosorbide Mononitrate241$3,370
Rosuvastatin Calcium272$3,113
Ezetimibe109$2,772
Carvedilol323$2,526

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$32$100,94398 claims
Boehringer IngelheimJardiance$17$31,61933 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 175 cardiovascular disease providers in Kansas.

Other cardiovascular disease in Olathe

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →